The 61% Insight: Our Launch Data Reveals Most PSP Patients Are Enrolled Mid-Treatment, Not at Day 1

The 61% Insight: Our Launch Data Reveals Most PSP Patients Are Enrolled Mid-Treatment, Not at Day 1
If your Patient Support Program is built only for "new-to-therapy" patients, you're overlooking the majority. Are you supporting the right patient journey?

When do you think a patient is enrolled in a Patient Support Program (PSP)? 

The common assumption for therapies with complex titration is "Day 1." We build our support models around the "initiation phase"—guiding a new patient through their first dose, managing early side effects, and establishing a routine. 

Real-world data from a recent PSP launch challenges this assumption directly. 

Our analysis of the patient cohort from this initial launch phase revealed a striking insight: 61% of all patients were enrolled after Week 1 of their treatment. 

This "61% cohort" isn't just a rounding error; it's the majority. It represents a second, distinct patient journey that most support programs are not designed to handle. 

The 'Intervention' Cohort vs. The 'Initiation' Cohort 

This data suggests that HCPs enroll patients at two critical, very different moments: 

  1. The 'Initiation' Cohort (39%): These patients are enrolled at Week 1. They are new to therapy, and their needs are clear: help with starting, managing expectations, and handling the initial titration steps. 

  2. The 'Intervention' Cohort (61%): This group is enrolled mid-treatment—at Week 8, Week 16, or even later. These are not "new starts." They are often enrolled precisely because an HCP has identified an adherence risk, a struggle with the dosing schedule, or a need for reinforced support long after the "initiation phase" has passed. 

A "one-size-fits-all" PSP that greets a Week 16 patient with a "Welcome to your first dose!" message is not just unhelpful; it's irrelevant. It immediately breaks trust and signals that the program doesn't understand the patient's real-world journey. 

This 61% insight proves that HCPs are using the PSP as both an initiation tool and an intervention tool. 

The Strategic Imperative: Segment and Personalize 

A modern PSP platform cannot treat these two patient populations the same way. Its value depends on its ability to be intelligent, flexible, and context-aware. 

  • For the 'Initiation' patient: The platform must provide proactive, time-based support focused on dose escalation and early side-effect management. 

  • For the 'Intervention' patient: The platform must be smart enough to meet them where they are. It needs to bypass the "new start" content and immediately offer support relevant to their current treatment week, whether that's reinforcing long-term persistence or managing later-stage challenges. 

This level of personalization is impossible if your platform is a simple content library. It requires a dynamic, data-driven solution. 

The data is clear: the majority of patients need support after they've already begun. The challenge for pharma is to have a platform ready to meet them. 

The StayOnTreatment.com platform is built for this reality. It allows for immediate patient segmentation upon enrollment, ensuring that whether a patient is on Day 1 or Day 100, they receive the right support at the right time, fully aligned with their HCP's goals.